Analyst Warns Of Structured-Product Back-Testing
Back-testing of a structured product can be a useful tool for investors, as long as the issuers ensure the tests are not viewed as a “predictive measure,” and that they don’t “cherry pick” the time period to make products appear better, according to Frank Copplestone, head of retail structured products for Europe, the Middle East and Africa at Morgan Stanley.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts
